Ireland
--:--IST
Recruiting Not applicable

Cerebellar Modulation of Cognition in Psychosis

NCT06107764 · tracked via the Priya Life Science Israel tracker
Sponsor
Mclean Hospital
Phase
Not applicable
Started
2024-07-31
Last updated
2026-08-20

Condition(s) studied

SchizophreniaSchizoaffective DisorderBipolar Disorder IPsychosis

Investigational drug(s) / intervention(s)

intermittant theta burst stimulation (iTBS)continuous theta burst stimulation (cTBS)sham rTMS

intermittant theta burst stimulation (iTBS): iTBS consists of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.

continuous theta burst stimulation (cTBS): cTBS consists of 3 pulses at 50 Hz repeated at 5 Hz (every 200ms) continuously for a total of 600 pulses

sham rTMS: sham rTMS does not deliver a significant change in magnetic field strength

Study summary

The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks).

Participants will be asked to perform cognitive tasks (problem-solving) and undergo brain scans before and after transcranial magnetic stimulation (TMS). TMS is a way to non-invasively change brain activity. Forms of TMS are FDA-approved to treat depression and obsessive compulsive disorder. In this study, we will use a different form of TMS to temporarily change brain activity to observe how that changes speed in problem-solving.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18-55 years * Diagnosis of a psychotic disorder (i.e. schizophrenia or schizoaffective disorder or bipolar disorder type I) * Must be able to read, speak and understand English * Must be judged by study staff to be capable of completing the study procedures * Participants will be in stable outpatient treatment with no recent (within the past 30 days) hospitalizations or changes in their medication regimens. Exclusion Criteria: * Diagnostic and Statistical Manual 5 diagnosis of moderate substance use disorder within the past month * Conditions that might result in increased risks of side effects or complications from rTMS or MRI, including: * Intracranial pathology from a known genetic disorder (e.g., Neurofibromatosis 1, tuberous sclerosis) or from acquired neurologic disease (e.g. stroke, tumor), cerebral palsy, history of severe head injury, or significant dysmorphology; * History of fainting spells of unknown or undetermined etiology that might constitute seizures * History of multiple seizures or diagnosis of epilepsy * Any progressive (e.g., neurodegenerative) neurological disorder such as multiple sclerosis or Parkinson's disease * Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) * Metal implants (excluding dental fillings) unless cleared by the responsible covering MD (i.e. MRI compatible joint replacement) * Pacemaker * Implanted medication pump * Vagal nerve stimulator * Deep brain stimulator or transcutaneous electric nerve stimulation unit * Ventriculo-peritoneal shunt * Signs of increased intracranial pressure * Intracranial lesion * History of head injury resulting in prolonged loss of consciousness (\>15minutes) or neurological sequelae * Pregnancy: All participants capable of becoming pregnant will be required to have a pregnancy test; any participant who is pregnant will not be enrolled in the study.

Primary outcome measure(s)

  • BACS Symbol Coding test — eight minutes before TMS and one minute after TMS on each of the three TMS visit days
    The BACS Symbol coding test is a test of information processing speed
  • BACS Digit Sequence test — five minutes before TMS and four minutes after TMS on each of the three TMS visit days
    The BACS digit sequence test is a test of working memory performance
  • functional Magnetic Resonance Imaging — fifteen minutes before TMS and nine minutes after TMS on each of the three TMS visit days
    resting-state (task free) functional connectivity

Trial sites (2)

FacilityCityRegionStatus
McLean Hospital Belmont Massachusetts Recruiting
Beth Israel Deaconess Medical Center Boston Massachusetts Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06107764 on ClinicalTrials.gov ↗ ← All trials in Israel